Objective: Comparison of systemic inflammatory markers NLR, CRP, and interleukin-6 between patients with acute ischemic stroke and controls, and evaluation of the value of these inflammatory biomarkers in assessing stroke severity according to the NIHSS score. Subjects and Methods: Cross-sectional study with control group was conducted, including 113 patients with cerebral infarction and 113 control subjects. Inflammatory markers assessed comprised neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), and interleukin-6 (IL-6). Disease severity was evaluated using NIHSS score. Results: The mean age was 65.03 ± 10.75 years, with 25.7% of patients having NIHSS ≥15. NLR was higher in the patient group compared to controls (4.11 vs 2.31; p<0.001). Similarly, CRP and IL-6 levels were elevated in the patient group (7.01 vs 3.01 mg/L and 11.94 vs 4.37 pg/mL, respectively; p<0.001). NLR showed a moderate correlation with NIHSS (r=0.599, p<0.001). CRP was positively correlated with NIHSS (r=0.429, p<0.001), while IL-6 demonstrated the strongest correlation (r=0.617, p<0.001). For identifying severe cerebral infarction, NLR had an AUC of 0.823 at a cut-off of 5.66; CRP had an AUC of 0.683 at a cut-off of 9.00 mg/L; and IL-6 had an AUC of 0.712 at a cut-off of 12.06 pg/mL. Conclusion: Systemic inflammatory biomarkers IL-6 and NLR show potential utility in supporting assessment of severity in patients with cerebral infarction.
THE VALUE OF SYSTEMIC INFLAMMATORY BIOMARKERS IN ASSESSING SEVERITY IN PATIENTS WITH CEREBRAL INFARCTION
26
Views
0
Downloads
Keywords
Cerebral infarction, inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), interleukin-6 (IL-6).
Abstract
References
[1]
Favate AS, Younger DS. Epidemiology of ischemic stroke. Neurologic Clinics. 2016;34(4):967–980. doi:10.1016/j.ncl.2016.06.013.
Google Scholar
[2]
Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. Journal of Leukocyte Biology. 2010;87(5):779–789. doi:10.1189/jlb.1109766.
Google Scholar
[3]
Bian J, Zhang L, Li H, et al. CRP as a potential predictor of outcome in acute ischemic stroke. Biomedical Reports. 2023;18(2):17. doi:10.3892/br.2022.1588.
Google Scholar
[4]
Song SY, Zhao XX, Rajah G, et al. Clinical significance of baseline neutrophil-to-lymphocyte ratio in patients with ischemic stroke or hemorrhagic stroke: an updated meta-analysis. Frontiers in Neurology. 2019;10:1032. doi:10.3389/fneur.2019.01032.
Google Scholar
[5]
Zhu F, Li X, Chen Y, et al. Correlations between NLR, NHR, clinicopathological characteristics and prognosis of acute ischemic stroke. Medicine (Baltimore). 2023;102(24):e33957. doi:10.1097/MD.0000000000033957.
Google Scholar
[6]
Papadopoulos A, Palaiodimou L, Ntaios G, et al. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98(10):e1002–e1012. doi:10.1212/WNL.0000000000200002.
Google Scholar
[7]
Shaafi S, Sharifipour E, Rahmanifar R, et al. Interleukin-6, a reliable prognostic factor for ischemic stroke. Iranian Journal of Neurology. 2014;13(2):70–76. (No DOI assigned).
Google Scholar
[8]
Bushnell C, Howard VJ, Lisabeth L, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2024;55(12):e344–e424. doi:10.1161/STR.0000000000000462.
Google Scholar
[9]
Jorepalli V, Reddy V, Prasad S, et al. Association between neutrophil-lymphocyte ratio and stroke severity using the NIHSS among patients in a tertiary care hospital. Journal of Rare Cardiovascular Diseases. 2025;5(3):234–240. (DOI currently not indexed).
Google Scholar
[10]
Jiang Y, Fan T. IL-6 and stroke recurrence in ischemic stroke. Biomarkers in Medicine. 2024;18(17-18):739–747. doi:10.2217/bmm-2024-0183.
Google Scholar